Pancreatic Cancer Europe is a European multi-stakeholder platform which aims at bringing together experts from all over Europe including academics, physicians, politicians, patient groups, journalists and industry with a common interest and willingness to improve care for patients with pancreatic cancer.
PCE – Pancreatic Cancer Inequality report
Today, Europe has large discrepancies in the incidence and prevalence of pancreatic cancer. These discrepancies are the result of genetic differences, as well as unequal exposure to environmental risk factors, itself the result of cultural differences. Levels of smoking, alcohol consumption, and also diabetes and obesity are different across Europe, which contribute to the variation in the incidence of pancreatic cancer.
Moreover, it seems that pancreatic cancer has been neglected for decades at the political level. National cancer plans seldom mention pancreatic cancer, and research funding is incredibly low for such a lethal cancer.
In this context, this inequality report delivers a comprehensive presentation of the different challenges surrounding pancreatic cancer. This report aims to put pancreatic cancer on the European and national agendas, so that the EU and its Member States can seize the opportunity to tackle one of the deadliest of all common cancers. We at Pancreatic Cancer Europe know it is our duty to inform and take action towards pancreatic cancer control, but we are not able to do it alone.
World Pancreatic Cancer Day 2018
On this 15th of November, 2018, all patients, families and communities unite for World Pancreatic Cancer Day. This day, we celebrate the common work through awareness-raising, research and policies to fight pancreatic cancer. We also want to dedicate this day to those who suffer from this terrible cancer. We at Pancreatic Cancer Europe want to support this effort and think of all the families in need of European and national action. Our work in the past months has led to the creation of several tools and documents which are designed to foster new policies addressing this disease.
Our inequality report presents the state of pancreatic cancer across Europe, with angles on diagnosis, research, national policies and unmet needs. It emphasises the inequalities that exist in Europe and the need for a harmonised policy to offer the same chances to all European citizens. Our heatmap, accessible online, also presents in an interactive way those inequalities by giving key information specific to each country. So far, eight countries are referenced, but we hope to add more, thanks to your help.
By 2020, pancreatic cancer will be the second killer cancer in Europe. Today should be about thinking to the future and how we can reverse the trend of increasing mortality and incidence in order to avoid this fearful prediction. Every action towards a new policy, every conversation to raise awareness, every breakthrough in diagnosing pancreatic cancer is a new step taken in our fight”.
Pancreatic Cancer Heatmap now online!
Following several months of development, we are happy to unveil the PCE heatmap. Conceived as a powerful tool to compare the pancreatic cancer patients’ situation in each European country, the heatmap provides information on awareness situation, national policy, diagnosis, research… We are always looking for more data and information to enrich the heatmap. Should you want to add some data for your country, please contact directly the Secretariat.
Endorsement of ESMO GI 2018
Pancreatic Cancer Europe is proud to endorse ESMO World Congress on Gastrointestinal Cancer 2018. The ESMO World Congress on Gastrointestinal Cancer is the premier global event in the field – encompassing malignancies affecting every component of the gastrointestinal tract and aspects related to the care of patients with gastrointestinal cancer, including screening, diagnosis and the latest management options for common and uncommon tumours. ESMO GI will take place in Barcelona, Spain – from the 20 to 23 June 2018. More information on their website www.worldgicancer.com.
Did you know that Pancreatic Cancer has the lowest survival rate of all cancers?
Help us to reverse the Trend!
Pancreatic cancer is currently the 4th leading cause of death by cancer in Europe. If no action is taken, it is set to be 2nd by 20203.
Launched in July 2014 a call for action on pancreatic cancer by Members of the European Parliament has been the key driver for the activities of the platform. Since its launch, Pancreatic Cancer Europe has been developping the Pancreatic Cancer Declaration, in order to ensure real change in European policies for pancreatic cancer patients.
Patients affected with pancreatic cancer lose 98% of their healthy life expectancy at the point of diagnosis5.
Today, a diagnosis of pancreatic cancer is generally associated with a death sentence and few patients are alive one year after diagnosis, while an earlier diagnosis could help reduce the mortality of the disease. If diagnosed in time, chances of survival increase.
- Farthing, M, Roberts, S, Samuel D, Williams D, et al. Survey of digestive health across Europe: Final report. Part 1: The burden of gastrointestinal diseases and the organisation and delivery of gastroenterology services across Europe, United European Gastroenterology Journal, December 2014 vol. 2 no. 6 539-543
- Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E, et al. European cancer mortality predictions for the year 2013. Annals of Oncol. 2013; 24:792-800
- Pancreatic Cancer Action Network. The alarming rise of pancreatic cancer deaths in The United States: Why we need to stem the tide today, 2012. www.pancan.org/wp-content/uploads/2013/01/incidence_report_2012_executive_summary.pdf [Last accessed April 2014]
- Carrato et al, 2015. “A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs.” DOI 10.1007/s12029-015-9724-1
- Carrato A, Falcone A, Ducreux, M, Valle, J, Parnaby A, Djazouli K, Alnwick-Allu K, Hutchings A, Palaska C, Parthenaki I. A systematic review of the burden of pancreatic cancer in Europe: Real-world impact on survival, quality-of-life, and costs. J Gastrointest Cancer 2015 Sep;46(3):201-11